BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

...NYSE:AZN) has the PAR2 antagonist mAb MEDI0618 in Phase I testing for osteoarthritis pain. TARGET/MARKER/PATHWAY: Kallikrein-related...
...E. Rothenberg, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio email: rothenberg@cchmc.org Claire Quang Cincinnati Children's Hospital Medical Center Kallikrein-related...
BioCentury | Feb 26, 2020
Deals

Bicycle’s bicyclic peptides attract Genentech as first corporate immuno-oncology partner

...peptides for ophthalmic diseases. ThromboGenics, now known as Oxurion N.V. (Euronext:OXUR), has the bicycle-based plasma kallikrein...
BioCentury | Feb 18, 2020
Regulation

Regulatory Roundup: PharmaMar-Jazz, BioCryst products under FDA review; plus EU approvals of Vyndaqel, Beovu; and more

...said FDA does not currently plan to hold an advisory committee meeting for the second-generation kallikrein...
BioCentury | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...royalties ranging in the mid-teens through 40%. BioCryst plans to submit a NDA for the kallikrein...
...HER4) (ErbB4) Epidermal growth factor receptor (EGFR) (ErbB1) (HER1) Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) CD19 Kallikrein Shape...
BioCentury | Jul 26, 2019
Company News

July 25 Company Quick Takes: RegenxBio, Neurimmune in neurodegenerative gene therapy deal; plus Lilly, Epizyme, ElevateBio and more

...gene therapy that delivers a gene encoding an antibody that targets and binds to plasma kallikrein...
BioCentury | May 21, 2019
Clinical News

BioCryst makes case for oral HAE therapy even as Phase III data disappoint investors

...and an MAA to EMA in 1Q20 for a 150 mg dose of the second-generation kallikrein...
...Targets: C1 esterase - Complement 1 esterase; KLKB1 - Plasma kallikrein Brian Moy, Assistant Editor BCX7353 BioCryst Pharmaceuticals Inc. Kallikrein Angioedema...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

...angioedema (HAE) attacks. The company plans to submit an NDA to FDA for the second-generation kallikrein...
BioCentury | Jan 25, 2019
Financial News

Attune raises $23M, reports safety data for angioedema candidate

...B round on the back of reporting Phase I data for its lead oral plasma kallikrein...
...Wong will join Attune's board. Attune Pharmaceuticals, New York, N.Y. Business: Inflammation Mark Zipkin ATN-249 Attune Pharmaceuticals Venrock Associates Plasma kallikrein...
BioCentury | Jan 25, 2019
Finance

Venrock spreads HAE bets

...$23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein...
...KLKB1 inhibitors KVD900 and KVD818 in Phase I testing for HAE. BioCryst's BCX7353, an oral kallikrein...
...Investments, RA Capital Advisors, Boxer Capital and Tang Capital Partners. Mark Zipkin, Staff Writer ATN-249 Attune Pharmaceuticals Venrock Associates Plasma kallikrein...
BioCentury | Jan 23, 2019
Financial News

Attune raises $23M, reports safety data for angioedema candidate

...round Wednesday on the back of reporting Phase I data for its lead oral plasma kallikrein...
...Capital and Tang Capital Partners. RTW's Rod Wong will join Attune's board. Mark Zipkin ATN-249 Attune Pharmaceuticals Venrock Associates Plasma kallikrein...
Items per page:
1 - 10 of 299